ADVERTISEMENT
Log in here to read the desired article.
This author has not written his bio yet.
But we are proud to say that Joachim Eeckhout contributed 135 entries already.
French biotech Cellectis is abandoning development of its two internal allogeneic CAR-T programs and repositioning itself as an in vivo gene editing company focused initially on cardiovascular disease.
Hanover-based Allogenetics has raised €3.8 million in a Pre-Series A round to advance ALG-115, an ex vivo gene therapy for donor lungs, through IND-enabling studies and toward a first-in-human trial planned for late 2027 or early 2028.
Simris Group is making amanitin-based ADCs the center of its strategy under former Heidelberg Pharma CEO Andreas Pahl — less than two months after hiring the executive who helped build Heidelberg Pharma’s own amanitin platform.
The Barcelona-based biotech will use the financing to complete a 30-patient Phase 2a study of its lead candidate CTH120, with the first efficacy data expected in mid-2027.
Dutch biotech Leyden Labs has reported positive Phase 1 results for intranasal RIG-101 and disclosed that it acquired the drug’s developer, RIGImmune, earlier this year.
Switzerland-based Pharvaris’ once-daily oral deucrictibant XR reduced hereditary angioedema (HAE) attacks by 83% versus placebo in a pivotal Phase 3 trial, putting the experimental prophylactic into roughly the same efficacy range as several leading injected treatments.
Spanish biotech Vaxdyn has raised an €11 million Series A to take K-VAX, its vaccine against Klebsiella pneumoniae and Acinetobacter baumannii, into a first-in-human Phase 1 trial. Portuguese investor Biovance Capital led the round with a €4 million investment, joined by the European Innovation Council (EIC) Fund and the Impacto Andalusia fund managed by Arcano Partners.
Copenhagen’s BioInnovation Institute (BII) is providing six early-stage companies with €1.3 million each in convertible loans, taking its total financing of each startup to €1.8 million.
Novartis’ pelacarsen failed to reduce cardiovascular events in the first Phase 3 outcomes trial of an Lp(a)-lowering drug, despite successfully lowering the genetically driven cardiovascular risk factor.
French biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a randomized Phase 1 trial remained disease-free after three years, while three of 16 patients in the control arm relapsed.